Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non–small cell lung cancers

作者：Jiefei Han, Ruofei Yu, Jianchun Duan, Jin Li, Wei Zhao, Guoshuang Feng, Hua Bai, Yuqi Wang, Xue Zhang, Rui Wan, Jiachen Xu, Xin Wang, Yanfang Guan, Xuefeng Xia, Zhuoran Yao, Kailun Fei, David P. Carbone, Zhijie Wang, Jie Wang · 发表于：Science Advances · 年份：2021 · DOI：10.1126/sciadv.abd6971 · 被引用次数：22 · 研究领域：Cancer Immunotherapy and Biomarkers、Lung Cancer Treatments and Mutations、Lung Cancer Research Studies

T cells (shared TCR clones). This index correlated with response and survival outcomes of anti-PD-(L)1 treatment. All the TCR sequences of neoantigen-stimulated T cells were included in the shared TCR clones, indicating that TCR clones involved in TIR index estimation represented tumor-specific T cells. Therefore, the TIR index is a feasible approach for assessing tumor-specific TCR and stratifying patients with NSCLC for anti-PD-(L)1 therapy.